Stock screenerAll disclosures →
EDGAR →
NMRA
Conviction 8HealthcareScan · Thu, Jun 25, 2026NMRA$1.51+3.42%
ResistanceSupportVol 14Vol MA14 4.67M
Mar 26Apr 14May 1May 19Jun 8Jun 25
Price1.51
Change+3.42%
Gap-1.37%
Rel volume0.27×
Avg volume3.53M
Avg $ vol5M
SMA 201.62
SMA 501.88
SMA 2002.19
Price vs 50-19.89%
Price vs 200-31.06%
MA stackbearish
50/200 cross—
Supertrendup · 0.8737
RSI (14)45
MACD hist0.01
MACD crossbull · 2d
Stoch %K / %D67 / 69
ADX (14)19
+DI / −DI22 / 30
RSI divergence—
MACD divergenceBullish
ATR %+13.93%
ADR %10.89%
52w high3.59
52w low0.7333
From 52w high-57.94%
Above 52w low+105.92%
New 52w highNo
SqueezeOff
Bollinger width50.14%
%B0.36
Donchian pos60.17%
Donchian high1.96
Donchian low0.8301
AVWAP (52w high)1.89
vs AVWAP high-20.15%
AVWAP (52w low)2.07
vs AVWAP low-26.89%
OBV trendFlat
Chaikin MF (20)0.31
Today vs 20d0.27×
Avg vol (14d)4.67M
Avg vol (20d)3.53M
Avg $ vol (20d)5M
Market cap279.78M
RS 3m (vs SPY)-53.15%
RS 6m (vs SPY)-24.31%
RS line new highNo
Trend template2/8
Technical rank16.0
1 week-1.31%
1 month-17.93%
3 months-39.60%
6 months-16.57%
1 year+86.79%
YTD-9.04%
P/E-1.18
P/B3.96
P/S—
P/FCF-1.35
EPS-1.45
Div yield—
ROE-335.21%
ROA-153.97%
Debt/Eq1.60
Current5.09
EV/EBITDA-1.02
Gross margin—
Net margin—
Rev growth—
EPS growth2.81%
Price target—
Target upside—
Analyst rating—
Institutional—
Ent. value245.67M
Revenue—
Net income-53.46M
Gross profit—
Free cash flow-206.56M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out185.28M
Employees92
ListedFri, Sep 15, 2023
Free float68.91M
Float %41.2%
Short interest5.58M
Days to cover5.0d
Short volume32.7%
Squeeze score41 / 100
Next earningsWed, Aug 5, 2026 (41d)
EPS forecast−$0.23 · 4 est
Last EPS vs est—
Last surprise—
Setup gradeD
Conviction8 / 100
Pattern quality—
Tech rank16.0 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance2.27
Support1.20
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in NMRA
No recent disclosed trades by Congress in NMRA. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in NMRA · 5 buys
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Fust Matthew K Director · Stock Option (Right to Buy) · 2026-05-27 | Grant | 80K | $0 | 2026-05-27 | 2026-05-29 |
Burow Kristina Director · Stock Option (Right to Buy) · 2026-05-27 | Grant | 80K | $0 | 2026-05-27 | 2026-05-29 |
Ho Maykin Director · Stock Option (Right to Buy) · 2026-05-27 | Grant | 80K | $0 | 2026-05-27 | 2026-05-29 |
Piacquad David Director · Stock Option (Right to Buy) · 2026-05-27 | Grant | 80K | $0 | 2026-05-27 | 2026-05-29 |
Halawa Alaa Director · Stock Option (Right to Buy) · 2026-05-27 | Grant | 80K | $0 | 2026-05-27 | 2026-05-29 |
SEC filings
EDGAR filings in NMRA · 1 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.
Start free — 7-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.